Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: September 2013

Chapter 22 - Prophylaxis for deep venous thrombosis and pulmonary embolism in surgery

from Section 6 - Hematology

Summary

Introduction

Venous thrombosis is a major cause of disability and death in all patient populations. Autopsy studies of hospitalized patients have demonstrated that massive pulmonary embolism (PE) is the cause of death in 5–10% of all hospital deaths and have suggested that two-thirds of all clinically important venous emboli are never recognized during life [1,2]. In a large multi-center study, 30,827 surgical patients were evaluated with respect to venous thromboembolism (VTE) risk and appropriate prophylaxis as recommended by the American College of Chest Physician (ACCP). This study showed that 19,842 surgical patients were considered at risk for VTE but only 11,613 (58.5%) received appropriate ACCP-recommended VTE prophylaxis [3]. More recently, the Surgical Care Improvement Project selected the application of VTE prophylaxis as a nationally reported metric for preventing VTE [4]. The purpose of this chapter is to review the pathophysiology of perioperative deep vein thrombosis (DVT), assess preoperative VTE risk and review the modalities of prophylaxis for preventing postoperative VTE in surgical patients.

Pathophysiology

The pathophysiologic changes of stasis, intimal injury, and hypercoagulability predispose surgical patients to the development of DVT or PE. The supine position on the operating room table, the anatomic position of the extremities for some surgical procedures, and the effect of anesthesia all contribute to stasis during surgery. Venographic contrast studies have shown that the supine position on the operating table decreases venous return [5,6]. In orthopedic, gynecologic, and urologic surgeries, the anatomic position of the body that provides the best surgical access to the operative site impairs adequate venous drainage during the procedure [7]. For example, in total hip replacement and hip fracture repair, the flexion and adduction of the hip that is required for better anatomic access to the surgical field has been shown to impair venous return [7]. Anesthesia causes peripheral venous vasodilation, which results in increased venous capacitance and decreased venous return during the operative procedure [8–10].

Related content

Powered by UNSILO
References
Carter, C, Gent, M.The epidemiology of venous thrombosis. In Colman, R, Hirsh, J, Marder, V, Salzman, E, eds. Hemostasis and Thrombosis. Philadelphia, PA: JB Lippincott; 1982, pp. 805–19.
Dismuke, S, Wagner, E.Pulmonary embolism as a cause of death: the changing mortality in hospitalized patients. J Am Med Assoc 1986; 255: 2039–42.
Cohen, A, Tapson, V, Bergmann, J et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE Study): a multi-national cross sectional study. Lancet 2008; 371: 387–94.
Surgical Care Improvement Project. Joint Commission website: .
Nicolaides, A, Kakkar, V, Renney, J.Soleal sinuses and stasis. Br J Surg 1970; 57: 307.
Nicolaides, A, Kakkar, V, Field, E et al. Venous stasis and deep vein thrombosis. Br J Surg 1972; 59: 713–16.
Stamatakis, J, Kakkar, V, Sagar, S et al. Femoral vein thrombosis and total hip replacement. Br Med J 1977; 112: 223–5.
Clark, C, Cotton, L.Blood flow in deep veins of the legs: recording technique and evaluation of method to increase flow during operation. Br J Surg 1968; 55: 211–14.
Lindstrom, B, Ahlman, H, Honsson, O et al. Blood flow in the calves during surgery. Acta Chir Scand 1977; 143: 335–9.
Linstrom, B, Ahlman, H, Jonsson, O et al. Influence of anesthesia on blood flow to the calves during surgery. Acta Anaesthesiol Scand 1984; 28: 201–3.
Johnson, R, Carmichael, J, Almond, H et al. Deep vein thrombosis following Charneley arthroplasty. Clin Orthop 1978; 132: 24–30.
Planes, A, Vochelle, N, Fagola, M.Total hip replacement and deep vein thrombosis: a venographic and necropsy study. J Bone Joint Surg 1990; 72B: 9–13.
Comerota, A, Stewart, G, Alburger, P et al. Operative venodilation: a previously unsuspected factor in the cause of postoperative deep vein thrombosis. Surgery 1989; 106: 301–9.
Schaub, P, Lynch, P, Stewart, G.The response of canine veins to three types of abdominal surgery: a scanning and transmission electron microscope study. Surgery 1978; 83: 411–22.
Stewart, G, Schaub, R, Niewiarowske, S.Products of tissue injury: their induction of venous endothelial damage and blood cell adhesion in the dog. Arch Pathol Lab Med 1980; 104: 409–13.
Stewart, G, Alburger, P, Stone, E et al. Total hip replacement induces injury to remote veins in a canine model. J Bone Joint Surg 1983; 65A: 97–102.
Gitel, S, Salvanti, E, Wessler, S et al. The effect of total hip replacement and general surgery on antithrombin III in relation to venous thrombosis. J Bone Joint Surg 1979; 61A: 653–6.
Eriksson, B, Eriksson, E, Wessler, S et al. Thrombosis after hip replacement: relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60: 159–63.
Kluft, C, Verheijen, J, Jie, A et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast acting inhibitor of tissue type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605–10.
D'Angelo, A, Kluft, C, Verheijen, J et al. Fibrinolytic shut down after surgery:impairment of the balance between tissue plasminogen activator and its specific inhibitors. Eur J Clin Invest 1985; 15: 308–12.
Geerts, WH, Bergqvist, D, Pineo, GF et al. Prevention of venous thromboembolism. Chest 2008; 133: S381–453.
Caprini, J.Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg 2010; 199: S3–10.
Bahl, V, Hu, HM, Henke, PK et al. A valid study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010; 2: 344–50.
Clagett, G, Reisch, J.Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208: 227–40.
Hirsh, J, Levine, M.Low molecular weight heparin. Blood 1992; 79: 1–17.
Weitz, J.Low molecular weight heparins. N Engl J Med 1997; 337: 688–98.
Samama, M.Synthetic direct and indirect factor Xa inhibitors. Thrombosis Res 2002; 106: 267–73.
Johanson, N, Lachiewicz, PF, Lieberman, JR et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroscopy. J Am Acad Ortho Surg 2009; 17: 183–96.
Mismetti, P, Laporte, S, Zufferey, P et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta analysis. J Thromb Haemost 2004; 2: 1058–70.
Caprini, J, Scurr, J, Hasty, J.Role of compression modalities in a prophylactic program for deep vein thrombosis. Semin Thromb Hemost 1988; 14: 77–87.
Gardner, A, Fox, R.The venous pump of the human foot: a preliminary report. Bristol Med Chir J 1983; 98: 109–14.
Fordyce, M, Ling, R.A venous foot pump reduces thrombosis after total hip replacement. J Bone Joint Surg 1992; 74B: 45–9.
Wilson, N, Das, S, Kakkar, V et al. Thrombo-embolic prophylaxis in total knee replacement: evaluation of the A-V impulse system. J Bone Joint Surg 1992; 74B: 50–2.
Colwell, C, Froimson, M, Mont, M et al. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low molecular weight heparin. J Bone Joint Surg Am 2010; 92: 527–35.
Raghavan, N, Frost, CE, Yu, Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74–81.
Jiang, X, Crain, EJ, Luettgen, JM et al. Apixaban, an oral direct factor Xa inhibitor, inhibitis human clot-bound factor Xa activity in vitro. Thromb Haemost 2009; 101: 780–2.
Luettgen, JM, Wang, Z, Seiffer, DA et al. Inhibition of measured thrombin generation in human plasma by apixaban: a predictive mathematical model based on experimentally determined rate constants. J Thromb Haemost 2007; 5 (Suppl. 2): p-T-633.
Frost, C, Yu, Z, Moore, K et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 2007; 5: P-M-664.
Kubitza, D, Becka, M, Wensing, G et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939: an oral, direct Factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873–80.
Kubitza, D, Becka, M, Voith, B et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412–21.
Perzborn, E, Strassburger, J, Wilmen, A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939, an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514–21.
Weinz, C, Schwartz, T, Kubitza, D et al. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056–64.
Ufer, M.Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572–85.
Kubitza, D, Becka, M, Zuehlsdorf, M et al. Effects of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral direct Factor Xa inhibitor, in healthy subjects, J Clin Pharmacol 2006; 46: 549–58.
Stangier, J, Rathgen, K, Stahle, H et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47–59.
Stangier, J, Rathgen, K, Stahle, H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292–303.
European Medicines Agency (EMEA). European public assessment report: Pradaxa. .
Stangier, J, Eriksson, BI, Dahl, OE et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555–63.
Stangier, J, Rathgen, K, Stahle, H et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9: 59–68.
Stangier, J, Stahle, H, Rathgen, K et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug (abstract). XXIst Congress of the International Society of Thrombosis and Haemostasis 2007; P-T-677. Available at: . Accessed 7/21/2011.
Stangier, J, Stahle, H, Rathgen, K et al. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin (abstract) XXIst Congress of the International Society of Thrombosis and Haemostasis 2007; P-W-672. Available at .
Van Ryn, J, Stangier, J, Naertter, S et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103(6): 1116–27.
Collins, R, Scrimogeour, A, Yusuf, S et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162–73.
Mismetti, P, Laporte, S, Darmon, JY et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913–30.
Agnelli, G, Bergqvist, D, Cohen, AT et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high risk abdominal surgery. Br J Surg 2005; 92: 1212–20.
Soderdahl, DW, Henderson, SR, Hansberry, KL.A comparison of intermittent pneumatic compression of the calf and whole leg in preventing deep venous thrombosis in urologic surgery. J Urol 1997; 157: 1774–6.
Nurmohamed, MT, van Riel, AM, Henkens, CM et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75: 233–8.
Agnelli, G, Piovella, F, Buoncristiani, P et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339: 80–5.
Goldhaber, SZ, Dunn, K, Gerhard-Herman, M et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122: 1933–7.
Collen, JF.Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest 2008; 134(2): 237–49.
Oates-Whitehead, RM, D'Angelo, A, Mol, B.Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynecological surgery. Cochrane Database Syst Rev 2003; 4: CD003679.
ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double blind randomized multicenter trial with venographic assessment Br J Surg 1997; 84: 1099–103.
Baykal, C, Al, A, Demirtas, E et al. Comparison of enoxaparin and standard heparin in gynecologic oncologic surgery: a randomized prospective double blind clinical study. Eur J Gynaec Oncol 2001; 22: 127–30.
Fricker, JP, Vergnes, Y, Schach, R et al. Low dose heparin versus low molecular weight heparin (Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988; 18: 561–7.
Heilmann, L, von Templehoff, GF, Kirkpatrick, C et al. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: efficacy, safety, and follow up. Clin Appl Thromb Hemost 1998; 4: 268–73.
Bergqvist, D, Agnelli, G, Cohen, AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–80.
Eriksson, BI, Lassen, MR, the PENTassaccharide in HIpFRActure Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multi-center, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337–42.
Lassen, MR, Raskob, GE, Gallus, A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Eng J Med 2009; 361: 594–604.
Lassen, MR, Raskob, GE, Gallus, A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807–15.
Lassen, MR, Gallus, A, Raskob, GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487–98.
Turpie, AG, Fisher, WD, Bauer, KA et al. BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479–86.
Eriksson, BI, Borris, LC, Dahl, OE et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374–81.
Eriksson, BI, Borris, L, Dahl, OE et al. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121–8.
Eriksson, BI, Borris, LC, Friedman, RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765–75.
Lassen, MR, Ageno, W, Borris, LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–86.
Kakkar, AK, Brenner, B, Dahl, OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31–9.
Turpie, AG, Lassen, MR, Davidson, BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673–80.
Ginsberg, JS, Davidson, BL, Comp, PC et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1–9.
Eriksson, BI, Dahl, OE, Rosencher, N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178–85.
Eriksson, BI, Dahl, OE, Rosencher, N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949–56.
Eriksson, BI, Dahl, OE, Huo, MH et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost 2011; 105(4): 721–9.
Bergqvist, D, Agnelli, G, Cohen, AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–80.
Rasmussen, MS, Jorgensen, LM, Wille-Jorgensen, P et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open label study. J Thromb Haemost 2006; 4: 2384–90.
Planes, A, Vochelle, N, Darmon, J et al. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996; 348: 224–8.
Bergqvist, D, Benoni, G, Bjorgell, O et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696–700.
Eikelboom, JW, Quinlan, DJ, Douketis, JD.Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet 2001; 358: 9–15.
Douketis, JD, Eikelboom, JW, Quinlan, DJ et al. Short duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162: 1465–71.
Cohen, AT, Bailey, CS, Alikhan, R et al. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001; 85: 940–1.